Baseline low-density lipoprotein cholesterol levels and outcome in patients with heart failure

The American Journal of Cardiology
Gideon CharachArdon Rubinstein

Abstract

The incidence of heart failure (HF) is constantly increasing in the Western world. Treatment with statins is well established for the primary and secondary prevention of cardiac events by lowering low-density lipoprotein (LDL) cholesterol levels. There are conflicting reports on the role of LDL cholesterol as an adverse prognostic predictor in patients with advanced HF. The aim of this study was to investigate the association between LDL cholesterol levels and clinical outcomes in 297 patients with severe HF (average New York Heart Association class 2.8). The mean follow-up period was 3.7 years (range 8 months to 11.5 years), and 37% of the patients died during follow-up. The mean time to first hospital admission for HF was 25 +/- 17 months. The study group was divided according to plasma LDL level < or =89, >89 to < or =115, >115 mg/dl. Patients with the highest baseline LDL cholesterol levels had significantly improved outcomes, whereas those with the lowest LDL cholesterol levels had the highest mortality. When analyzed with respect to statin use, it emerged that the negative association between LDL cholesterol level and mortality was present only in the patients with HF who were treated with statins. In conclusion, lower LD...Continue Reading

References

Sep 1, 1990·The Journal of Clinical Investigation·H W HarrisJ H Rapp
Nov 1, 2000·Critical Care Medicine·P FraunbergerD Seidel
Dec 10, 2003·Journal of the American College of Cardiology·Mathias RauchhausStefan D Anker
Jan 30, 2004·JAMA : the Journal of the American Medical Association·Yongmei LiuMichael J Klag
Apr 2, 2005·Zeitschrift für Kardiologie·M BöhmD J van Veldhuisen
Sep 1, 2005·Circulation·Inder S AnandUNKNOWN Val-HeFT Investigators
Jan 10, 2006·Journal of the American Geriatrics Society·Valérie TikhonoffJan A Staessen
Jul 11, 2006·American Heart Journal·Amresh RainaDaichi Shimbo
Nov 2, 2006·JAMA : the Journal of the American Medical Association·Alan S GoJerry H Gurwitz
Dec 13, 2006·American Heart Journal·Nasim AfsarmaneshGregg C Fonarow
Oct 12, 2007·The New England Journal of Medicine·Ian FordUNKNOWN West of Scotland Coronary Prevention Study Group
Nov 16, 2007·Fundamental & Clinical Pharmacology·Lars GullestadPål Aukrust
Dec 23, 2008·Current Atherosclerosis Reports·Michael Clearfield

❮ Previous
Next ❯

Citations

Nov 28, 2012·World Journal of Cardiology·Gideon CharachJacob George
Jun 24, 2010·Heart Failure Reviews·Petra KleinbongardGerd Heusch
Feb 16, 2017·Scientific Reports·Grzegorz KopećPiotr Podolec
Sep 15, 2016·Circulation. Heart Failure·Amanda R VestP Christian Schulze
Jun 16, 2010·Current Opinion in Cardiology·Timo E Strandberg
Jun 11, 2010·Current Opinion in Cardiology

❮ Previous
Next ❯

Related Concepts

Related Feeds

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.

Brain Ischemia

Brain ischemia is a condition in which there is insufficient blood flow to the brain to meet metabolic demand. Discover the latest research on brain ischemia here.

Cardiovascular Diseases: Risk Factors

Cardiovascular disease is a significant health concern. Risk factors include hypertension, obesity, dyslipidemia and smoking. Women who are postmenopausal are at an increased risk of heart disease. Here is the latest research for risk factors of cardiovascular disease.

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.

Cardiomyopathy

Cardiomyopathy is a disease of the heart muscle, that can lead to muscular or electrical dysfunction of the heart. It is often an irreversible disease that is associated with a poor prognosis. There are different causes and classifications of cardiomyopathies. Here are the latest discoveries pertaining to this disease.